US FDA (Food and Drug Administration) has approved Vanta, a high-performance recharge-free implantable neurostimulator (INS) from Dublin headquartered Medtronic. The device promises extended battery life and can last up to 11-years or 10% longer than the company’s last-generation neurostimulator, the PrimeAdvanced device. Vanta is also 20% smaller than the previous generation device. Also Read: FDA warns against use of Medtronic’s HeartWare device for patients with end-stage heart failure
Vanta features: Vanta neurostimulator uses Medtronic’s proprietary AdaptiveStim tech for pain relief that adjusts according to the patient’s movement or body position using an in-built accelerometer. The AdaptiveStim tech automatically alters the stimulation to sustain each patient’s ideal dose. Also Read: Cancer treatment: Nanobiotix and LianBio team up, expands therapeutic possibilities for patients with radioenhancer NBTXR3 therapy
- The Vanta neurostimulator provides full-body MRI access with Medtronic SureScan technology
- Vanta system provides access to Snapshot reporting, Medtronic’s proprietary data insights solution
- Vanta neurostimulator also comes with a mobile application and web portal called CareGuidePro. It serves as a virtual guide for patients throughout their Medtronic spinal cord stimulation therapy journey.
Existing competitors: In 2019,Abbott had launched Proclaim XR recharge-free neurostimulation system with a battery life of up to 10 years with lower doses of spinal cord stimulation (SCS). Boston Scientific also has WaveWriter Alpha Spinal Cord Stimulator (SCS) System in its pain management portfolio and includes both rechargeable and non-rechargeable, 16- and 32-contact options. Also Read: COVID-19 vaccines: mRNA-based Pfizer and Moderna jabs causing heart inflammation in young population
What’re they saying: “We are committed to delivering innovative solutions that meet the needs of every patient,” said Charlie Covert, vice president and general manager, Pain Therapies within the Neuromodulation business, which is part of the Neuroscience Portfolio at Medtronic. “For those who prefer or require a recharge-free device, I believe the Vanta neurostimulator offers the best hardware and features available today. We are pleased to offer this solution, which is now part of the strongest and broadest overall portfolio in this market.”
Krishnan Chakravarthy, M.D., PhD, a San Diego-based interventional pain management physician said, “The extended battery life, broad MRI compatibility and personalized relief through AdaptiveStim technology allow for a more hassle-free experience and greater freedom for my patients as we manage their chronic pain.” Also Read: Weight Loss: It will now be easier to shed extra pounds after FDA’s nod of approval to anti-obesity drug ‘Wegovy’